Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan and Pfizer have agreed to settle their patent litigation with Sanofi-Aventis over pre-filled injections designed to treat severe allergic reactions.
Subscribe to our email newsletter
Meridian Medical Technologies, a Pfizer subsidiary, has signed a settlement agreement with Intelliject and Sanofi that will resolve pending patent litigation related to Intelliject’s NDA for its epinephrine auto-injector (e-cue).
Under the settlement agreement, Intelliject and Sanofi may launch e-cue no earlier than 15 November 2012, subject to receipt of final approval from the FDA.
Meridian manufactures e-cue and Mylan Specialty commercializes the product in the US.
Mylan CEO Heather Bresch said the EpiPen Auto-Injector will continue to be a market leader, given the proud, 20-year heritage of this important treatment for anaphylaxis.